CAI — CARIS LIFE SCIENCES, INC. COMMON STOCK (Healthcare >> Biotechnology)
CAI FAQ
What is CAI's P/E ratio?
CARIS LIFE SCIENCES, INC. COMMON STOCK (CAI) currently trades at a P/E ratio of 47.88.
What is CAI's ROE?
CARIS LIFE SCIENCES, INC. COMMON STOCK reports a Return on Equity (ROE) of 5.73%.
What is CAI's dividend yield?
CARIS LIFE SCIENCES, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is CAI's Deepscope Quality Score?
Deepscope rates CAI's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CAI?
Deepscope's AI Timing Score for CAI is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CAI belong to?
CARIS LIFE SCIENCES, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 17.97
Price
-0.03
(-0.17%)
Day Change
|
|
|---|
CAI Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 17.97 |
| PBV / Sector |
8.57 / 4.91
|
| Earning Per Share | 0.12 |
| PE / Sector |
47.88 / 18.34
|
| PEG or PE/Growth / Sector |
-1.75 / 0.61
|
| Average 1M Daily Value |
44.13 M
GREAT
|
| Average 1W Daily Value |
46.16 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
50% |
| Khả năng kiếm lợi nhuận |
|
60% |
| Lợi tức cho nhà đầu tư |
|
8% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-13 11:13:06 |
| Symbol | CAI |
| Name | CARIS LIFE SCIENCES, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 282.68 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,088.25 / 9,034.83 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 750 West John Carpenter Freeway, Irving, TX, United States, 75039
Phone: 866 771 8946
Website: https://www.carislifesciences.com
Employees: 1,846
Sector: Healthcare >> Biotechnology
Description: Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google